« Return to News | Awards & Advancement

Orwin joins Array BioPharma’s board of directors

Friday, November 9, 2012 02:29 PM

Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs for the treatment of cancer, has appointed John A. Orwin, CEO of Affymax, to Array's board of directors as part of its continued evolution toward late-stage development and commercialization.

Orwin has served as CEO of Affymax since 2011, after joining the company in 2010 as its COO. Previously, he held leadership roles in marketing, sales and operations for major pharmaceutical companies including Genentech, Johnson & Johnson, Alza Pharmaceuticals, Rhone-Poulenc Rorer and Schering-Plough.

Orwin brings a track record of substantial accomplishment in the pharmaceutical industry to Array's board of directors. Over his career, he has built successful businesses and commercialized a range of blockbuster products. Most recently, he led the approval and launch of Omontys, a hematology product for the treatment of anemia in chronic kidney disease. Prior to joining Affymax, he led Genentech's BioOncology business unit and grew a portfolio of cancer-fighting products including Avastin, Rituxan, Herceptin and Tarceva to over $7 billion in U.S. sales.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.